Acknowledgements This work was supported in part by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (23K06113) and World Premier International Research Center Initiative (WPI), MEXT, Japan
In FLOW trial data, approximately 18% of semaglutide-treated patients showed improved or stable kidney function markers over 2+ years
"Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial"
When you repair that underlying biology, everything else starts to get easier
There is no universal UK requirement to stop GLP-1 medications before all procedures
Only a small part of patients experienced a flare after the initial improvement (103, 104)